WO2022239876A1 - Iontherapy apparatus for the causal treatment of hepatitis, diabetes and obesity - Google Patents

Iontherapy apparatus for the causal treatment of hepatitis, diabetes and obesity Download PDF

Info

Publication number
WO2022239876A1
WO2022239876A1 PCT/KP2022/000054 KP2022000054W WO2022239876A1 WO 2022239876 A1 WO2022239876 A1 WO 2022239876A1 KP 2022000054 W KP2022000054 W KP 2022000054W WO 2022239876 A1 WO2022239876 A1 WO 2022239876A1
Authority
WO
WIPO (PCT)
Prior art keywords
iontherapy
mounting frame
motion part
treatment unit
fixed
Prior art date
Application number
PCT/KP2022/000054
Other languages
French (fr)
Inventor
Kwang Chun Kim
Original Assignee
Kwang Chun Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kwang Chun Kim filed Critical Kwang Chun Kim
Publication of WO2022239876A1 publication Critical patent/WO2022239876A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H7/00—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for
    • A61H7/002—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for by rubbing or brushing
    • A61H7/004—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for by rubbing or brushing power-driven, e.g. electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/01—Constructive details
    • A61H2201/0119—Support for the device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/01—Constructive details
    • A61H2201/0192—Specific means for adjusting dimensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/12—Driving means
    • A61H2201/1207—Driving means with electric or magnetic drive
    • A61H2201/1215—Rotary drive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/14—Special force transmission means, i.e. between the driving means and the interface with the user
    • A61H2201/1463—Special speed variation means, i.e. speed reducer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/14—Special force transmission means, i.e. between the driving means and the interface with the user
    • A61H2201/1481—Special movement conversion means
    • A61H2201/149—Special movement conversion means rotation-linear or vice versa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/16—Physical interface with patient
    • A61H2201/1657—Movement of interface, i.e. force application means
    • A61H2201/1664—Movement of interface, i.e. force application means linear
    • A61H2201/1669—Movement of interface, i.e. force application means linear moving along the body in a reciprocating manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/16—Physical interface with patient
    • A61H2201/1657—Movement of interface, i.e. force application means
    • A61H2201/1671—Movement of interface, i.e. force application means rotational
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/16—Physical interface with patient
    • A61H2201/1657—Movement of interface, i.e. force application means
    • A61H2201/1676—Pivoting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/16—Physical interface with patient
    • A61H2201/1683—Surface of interface
    • A61H2201/169—Physical characteristics of the surface, e.g. material, relief, texture or indicia

Definitions

  • This invention relates to a physical therapy apparatus to treat hepatitis, diabetes and obesity causally.
  • Chronic hepatitis and diabetes are the malignancies defined by WHO and it is very important and urgent to establish the effectual therapeusis for the malignancies in the medical field.
  • insulin therapy is a treatment to supply lacking insulin to human body. This therapy also has a defect that it is not a causal treatment and insulin should be injected without interruption during life. Furthermore, the utilization ratio of insulin is low on the patients of insulin resistance and insulin cannot be used on the patients producing side-effect on it.
  • the purpose of this invention is to overcome the defects of the previous therapies for hepatitis and diabetes and provide a physical therapy apparatus that has remarkable therapeutic value, doesn’t cause harmful side effects and can treat hepatitis, diabetes and obesity causally in the monotherapy.
  • This invention relates to a physical therapy apparatus to treat chronic active hepatitis B and cirrhosis, diabetes and obesity causally.
  • the physical therapy apparatus of the invention is an iontherapy apparatus in which an ion resin rod made of cation exchange resin is installed.
  • the movements restore the morbid charged status to normal one in the projected part of the diseased viscus, so that the progressive processes of inflammation, namely, blood circulatory disturbance (congestion and hemostasis) and
  • the therapy by using the iontherapy apparatus is also effective for the treatment of obesity because subcutaneous and visceral fat are decomposed by thermal, contact and electric stimulus occurred when rubbing the skin with the ion resin rod.
  • Figure 2 is a schematic front view of a treatment unit of the iontherapy apparatus of Figure 1 ;
  • Figure 3 is a partial cross sectional view in the direction A-A of the treatment unit of Figure 2.
  • the iontherapy apparatus (10) of the invention comprises a treatment unit (100), a mounting frame (200), a supporting structure (300), a buffer unit (400) and a height control unit (500).
  • the mounting frame (200) acts with the buffer unit (400) so that the treatment unit (100) is placed safely.
  • the mounting frame (200) is combined with the supporting
  • the buffer unit (400) comprises one or more buffer bands (410) fixed on the mounting frame (200).
  • the buffer unit (400) may comprise one or more buffer springs combined with the mounting frame (200) and the treatment unit (100).
  • the buffer unit (400) enables an ion resin rod (135) to be placed vertically on the skin and plays a role to keep the suitable compression strength of the ion resin rod (135).
  • the height control unit (500) comprises one or more height control bolts (510) and one or more height control nuts (520) combined with the mounting frame (200) and the supporting structure (300).
  • the height control unit (500) enables the treatment unit (100) to move up and down by controlling the distance between the mounting frame (200) and the supporting structure (300) by rotating the height control nuts (520), and to keep the suitable height.
  • the treatment unit (100) comprises a translation motion part (110), a circular motion part (120) and a rotation motion part (130).
  • the treatment unit (100) enables the ion resin rod (135) to move along a helical trajectory over its rotation motion in cooperation among the three parts.
  • the translation motion part (110) comprises a fixed plate (111), an electric motor (112) fixed on the end of the fixed plate (111), a reduction gear (113) coupled with the electric motor (112), a swivel bolt (117) linked to the shaft of the reduction gear (113), a moving nut (118) in screwed combination with the swivel bolt (117), two guide boxes (116) and two guide shafts (114) and a moving plate (115) fixed in the bottom of the two guide boxes (116), and enables the ion resin rod (135) to shuttle.
  • the circular motion part (120) comprises an electric motor (122) and a reduction gear (123) fixed to the moving nut (118) of the translation motion part (110), a turning axle (124) linked to the shaft of the reduction gear (123), a turning plate (125) and a rotator (126) fixed to the turning axle (124) and a stator (127) touched with the rotator (126) and fixed in the bottom of the moving plate (115) of the translation unit (110), and enables the ion resin rod (135) to draw a circle.
  • the electric motor (122) is energized
  • the turning axle (124) rotates at about 120 times per minute by the reduction gear (123).
  • the rotation motion part (130) circulates along the circular track with the radius of 3 centimeters by the turning plate (125) fixed to the turning axle (124).
  • the buffer spring (131) fixed to the electric motor (132) plays buffer action when the ion resin rod (135) moves on the surface of the skin.
  • the buffer unit of the iontherapy apparatus may comprise one or more buffer bands fixed on the mounting frame or one or more buffer springs combined with the mounting frame and the treatment unit.
  • Table 1 The values in Table 1 were measured after 24 weeks of tenofovir treatment in the control groups and after 12 weeks of treatment with the iontherapy apparatus in the experimental groups.
  • the said patients stopped taking oral antidiabetic drug while injected with increasing insulin and treated with iontherapy.
  • the blood glucose levels rose above initial levels from 7 th to 14 th day after switching to combined modality therapy and gradually fell after 21-25 days of the iontherapy.
  • the quantity of insulin gradually decreased as the blood glucose level fell.

Abstract

A physical therapy apparatus (10) can treat hepatitis, diabetes and obesity effectively by contacting an ion resin rod (135) made of cation exchange resin with skin. The apparatus (10) comprises a treatment unit (100) comprising a translation motion part (110), a circular motion part (120) and a rotation motion part (130), and a mounting frame (200) and a supporting structure (300) for installation of the treatment unit (100), and a buffer unit (400) used for setting the treatment unit (100) on the mounting frame (200) and acting as a buffer between the treatment unit (100) and the mounting frame (200), and a height control unit (500) for controlling the distance between the mounting frame (200) and the supporting structure (300).

Description

lontherapy apparatus for the causal treatment of hepatitis, diabetes and obesity
Field of the Invention This invention relates to a physical therapy apparatus to treat hepatitis, diabetes and obesity causally.
Background and Purpose of the Invention
Chronic hepatitis and diabetes are the malignancies defined by WHO and it is very important and urgent to establish the effectual therapeusis for the malignancies in the medical field.
In the treatment of hepatitis, chronic hepatitis B in particular, entecavir or tenofovir are now in wide use. But the treatment by using entecavir or tenofovir these medicaments can not recover the main functions of hepar such as elimination of toxicants and synthesis of albumin in the hepatic cells and have a drawback that the patient has to take medicine continuously during his lifetime.
In the treatment of diabetes, nowadays the treatment by using stem cell is recognized as an advanced and causal one, but it is expensive and unused widely because it is a surgical treatment. As a pharmacotherapy, insulin therapy is a treatment to supply lacking insulin to human body. This therapy also has a defect that it is not a causal treatment and insulin should be injected without interruption during life. Furthermore, the utilization ratio of insulin is low on the patients of insulin resistance and insulin cannot be used on the patients producing side-effect on it.
Further, there is no physical therapy apparatus that treats hepatitis, diabetes and obesity causally and has remarkable therapeutic value except surgical treatment and
1 pharmacotherapy in this field.
The purpose of this invention is to overcome the defects of the previous therapies for hepatitis and diabetes and provide a physical therapy apparatus that has remarkable therapeutic value, doesn’t cause harmful side effects and can treat hepatitis, diabetes and obesity causally in the monotherapy.
Brief description of the Invention
This invention relates to a physical therapy apparatus to treat chronic active hepatitis B and cirrhosis, diabetes and obesity causally. The physical therapy apparatus of the invention is an iontherapy apparatus in which an ion resin rod made of cation exchange resin is installed.
All living beings, both animal and plant, consist mostly of body fluids, electrolyte, and existance and transfer of charges in the electrolyte form electric and magnetic fields. Biological oxidation and reduction reactions and transmission of neural impulse are all related to the transfer of charges in the living beings.
When the ion resin rod made of cation exchange resin moves around the surface of the skin on which the diseased tissue of the human body is projected while contacted with it, frictional heat generated up to 60-80 °C by the friction between the ion resin rod and the skin, the while movements of cations occur in the ion resin rod. The movements lower the morbid potential of the projected part and return pH value to normal one in the diseased tissues.
That is to say, the movements restore the morbid charged status to normal one in the projected part of the diseased viscus, so that the progressive processes of inflammation, namely, blood circulatory disturbance (congestion and hemostasis) and
2 the anaerobic metabolic processes in the diseased tissues are arrested and pH value is restored to normal one in the local region. As the result, the inflammation which find expression in effusion, degeneration and growth step is inhibited.
And furthermore, the therapy by using the iontherapy apparatus is also effective for the treatment of obesity because subcutaneous and visceral fat are decomposed by thermal, contact and electric stimulus occurred when rubbing the skin with the ion resin rod.
Brief Description of the Drawings
An exemplary embodiment of the present invention will be described with reference to the accompanying drawings, in which:
Figure 1 is a schematic front view and side view of an iontherapy apparatus according to the exemplary embodiment;
Figure 2 is a schematic front view of a treatment unit of the iontherapy apparatus of Figure 1 ;
Figure 3 is a partial cross sectional view in the direction A-A of the treatment unit of Figure 2.
Detailed Description of Exemplary Embodiment
The iontherapy apparatus (10) of the invention comprises a treatment unit (100), a mounting frame (200), a supporting structure (300), a buffer unit (400) and a height control unit (500).
The mounting frame (200) acts with the buffer unit (400) so that the treatment unit (100) is placed safely. The mounting frame (200) is combined with the supporting
3 structure (300) so that the mounting frame (200) can move up and down by guide shaft (210), guide groove (310) and height control unit (500).
The buffer unit (400) comprises one or more buffer bands (410) fixed on the mounting frame (200). The buffer unit (400) may comprise one or more buffer springs combined with the mounting frame (200) and the treatment unit (100).
The buffer unit (400) enables an ion resin rod (135) to be placed vertically on the skin and plays a role to keep the suitable compression strength of the ion resin rod (135).
The height control unit (500) comprises one or more height control bolts (510) and one or more height control nuts (520) combined with the mounting frame (200) and the supporting structure (300).
The height control unit (500) enables the treatment unit (100) to move up and down by controlling the distance between the mounting frame (200) and the supporting structure (300) by rotating the height control nuts (520), and to keep the suitable height.
The treatment unit (100) comprises a translation motion part (110), a circular motion part (120) and a rotation motion part (130). The treatment unit (100) enables the ion resin rod (135) to move along a helical trajectory over its rotation motion in cooperation among the three parts. The translation motion part (110) comprises a fixed plate (111), an electric motor (112) fixed on the end of the fixed plate (111), a reduction gear (113) coupled with the electric motor (112), a swivel bolt (117) linked to the shaft of the reduction gear (113), a moving nut (118) in screwed combination with the swivel bolt (117), two guide boxes (116) and two guide shafts (114) and a moving plate (115) fixed in the bottom of the two guide boxes (116), and enables the ion resin rod (135) to shuttle. Once the
4 forward voltage is impressed on the electric motor (112), the swivel bolt (117) linked to the shaft of the reduction gear (113) turns on its axis in forward direction and it removes the moving nut (118) to the right. At the same time, a reduction gear (123) fixed to the moving nut (118), the moving plate (115) fixed to the reduction gear (123) and the two guide boxes (116) fixed to the moving plate (115) also move to the right along the two guide shafts (114). If the guide box (116) moves to the end of the guide shaft (114), the electric motor (112) automatically rotates in backward direction by an automatic switching circuit and the moving plate (115) moves to the left.
The circular motion part (120) comprises an electric motor (122) and a reduction gear (123) fixed to the moving nut (118) of the translation motion part (110), a turning axle (124) linked to the shaft of the reduction gear (123), a turning plate (125) and a rotator (126) fixed to the turning axle (124) and a stator (127) touched with the rotator (126) and fixed in the bottom of the moving plate (115) of the translation unit (110), and enables the ion resin rod (135) to draw a circle. Once the electric motor (122) is energized, the turning axle (124) rotates at about 120 times per minute by the reduction gear (123). At the same time, the rotation motion part (130) circulates along the circular track with the radius of 3 centimeters by the turning plate (125) fixed to the turning axle (124).
The rotation motion part (130) comprises a buffer spring (131) combined with the turning plate (125) of the circular motion part (120), an electric motor (132) combined with the buffer spring (131), a connecting rod (134) connecting the motor shaft with the ion resin rod (135) and the ion resin rod (135) and enables the ion resin rod (135) to turn on its axis. Once an electric current is sent to the electric motor (132) through the rotator (126) fixed to the turning axle (124) and the stator (127) fixed in the bottom of the moving plate (115), the ion resin rod (135) connected with the motor shaft turns
5 on its axis. The buffer spring (131) fixed to the electric motor (132) plays buffer action when the ion resin rod (135) moves on the surface of the skin.
The ion resin rod (135) installed in the rotation motion part (130) is a columnar cation exchange resin 11 millimeters in diameter and 13 millimeters in length, and the end which comes into contact with the skin is shaped like a dome. The iontherapy apparatus (10) rubs the skin of the focal region evenly in cooperation among the three motions of the ion resin rode (135) by the translation motion part (110), the circular motion part (120) and the rotation motion part (130) of the treatment unit (100), and takes thermal stimulus effect, ion emission effect and skin-stimulating effect in the course. The iontherapy apparatus can treat hepatitis, diabetes and obesity effectively through the such effects.
The descrived embodiments should not be construed as limitative. For example, the buffer unit of the iontherapy apparatus may comprise one or more buffer bands fixed on the mounting frame or one or more buffer springs combined with the mounting frame and the treatment unit.
The curative values of the iontherapy apparatus for hepatitis, diabetes and obesity are as follows:
1 ) Antiviral effects on hepatitis B virus
Table 1 . Antiviral effects on hepatitis B virus
Figure imgf000008_0001
6
Figure imgf000009_0001
The values in Table 1 were measured after 24 weeks of tenofovir treatment in the control groups and after 12 weeks of treatment with the iontherapy apparatus in the experimental groups.
As shown in Table 1 , 74, 73.9% had undetectable HBV-DNA in the control groups and 92, 91.3% in the experimental groups, 67, 61% had ALT normalization in the control groups and 90, 89% in the experimental groups, and 22% had undetectable
HBeAg negative in the control group and 100% in the experimental group. HBeAg seroconversion was observed in 21% of the patients in the control group and 75% in the experimental group. All the values in the experimental groups were slightly higher than in the control groups.
2) Changes in biochemical parameters measured by autoanalyzer Table 2. Change of main parameters of liver function (n=32)
Figure imgf000009_0002
The effectiveness was assessed by comparing between the main parameters of
7 liver function prior to and after the treatment.
Any drug or therapy to raise synthetic capacity of ALB in hepatic cells was not disclosed in prior arts. But in the treatment with the iontherapy apparatus, elevation of ALB was recognized in 32 patients (93.8%) and there was no significant difference in 2 patients (6.2%).
After the treatment with the iontherapy apparatus, in GGT tests, 26 patients (81 .3%) had GGT normalization and 6 patients (18.7%) had sharp reduction in GGT and this result shows that the treatment with the iontherapy apparatus had high ability to dissolve toxic agents in hepatic cells. In CHO tests, 2 of 32 patients (28.1%) were not exceeding 130mg/dl, 10 patients (31.3%) in 130~150mg/dl, 6 patients (18.8%) in 151 ~200mg/dl and 7 patients (21.8%) were not less than 200mg/dl before the treatment with the iontherapy apparatus. After the treatment, all the patients not exceeding 130mg/dl had the increased CHO levels not less than 140mg/dl with the increase of ALB and all the patients not less than 200mg/dl had the decreased CHO levels not exceeding 180mg/dl.
None of patients had been treated with the iontherapy apparatus in the region of the kidney, but most patients had Cre normalization in Cre tests and all the patients had high values in PLT tests.
3) Changes in blood glucose levels prior to and after the treatment with the iontherapy apparatus in Type 2 diabetic patients for which the treatment was efficacious
Table 3. Changes in blood glucose levels (n=78)
Figure imgf000010_0001
8
Figure imgf000011_0001
As shown in Table 3, of 16 incipient patients who have already diabetic symptoms, but were casually found by blood glucose test, 8 (50.0%) had normal blood glucose levels after 30 days of the treatment with the iontherapy apparatus, 4 (25.0%) after 40 days and the remaining 4 patients (25.0%) after 60 days, and in all 16 patients, relapse didn’t occur after leaving hospital.
In 18 patients who was treated with oral antidiabetic drug, but stopped treating with it after entering hospital and then was treated with the iontherapy apparatus, the blood glucose levels rose from 12th to 20th day after switching to the iontherapy and fell gradually after 21~25 days of the iontherapy. The lengths of treatment were different according to status of the pancreas. In 5 patients (27.8%) who were diagnosed as slight atrophy of the pancreas in ultrasonography, the mean pre-dinner blood glucose values were 162mg/dl after 60 days of the iontherapy, and in 13 patients (72.2%) who had no atrophy of the pancreas, the mean pre-dinner blood glucose values were 122.7mg/dl after 60 days of the iontherapy.
9 In a total of 29 patients, who had kept blood glucose levels with insulin therapy from the initial stage of diabetes, the quantity of insulin was gradually decreased from 14—21 days of the iontherapy. 6 patients (20.7%), who were diagnosed as slight atrophy of the pancreas in ultrasonography, received 10—16 U/day pre-mixed insulin twice a day after 2-3 months of the iontherapy and such a therapy kept the pre-dinner blood glucose levels at 110~130mg/dl 23 patients (79.3%), who had no atrophy of the pancreas, was treated with insulin decreased gradually and iontherapy for 50-60 days and with only iontherapy for 30 days. In result, the pre-dinner blood glucose levels were kept at 110~126mg/dl. After leaving hospital, relapses occurred in 7 (24.1%) of 29 patients, who disregard regimen, and relapse didn’t occur in the remaining 22 patients (75.9%) in 300 days.
15 patients, who had been treated with oral antidiabetic drug and insulin for 10 years or more, were treated with combined modality therapy using insulin and iontherapy apparatus because of insulin resistance caused by insulinizing for a long time.
8 patients (53.3%) were diagnosed as slight atrophy of the pancreas in ultrasonography and 7 patients (46.7%) have severe pathologic change of the pancreas and were diagnosed as fatty liver.
The said patients stopped taking oral antidiabetic drug while injected with increasing insulin and treated with iontherapy. The blood glucose levels rose above initial levels from 7th to 14th day after switching to combined modality therapy and gradually fell after 21-25 days of the iontherapy. The quantity of insulin gradually decreased as the blood glucose level fell.
8 patients, who were diagnosed as atrophy of the pancreas in ultrasonography, were treated with the iontherapy apparatus for 60 days and then were treated with the
10 iontherapy apparatus while injected with 10~16 U/day pre-mixed insulin in the morning and evening for 30 days. As the result, the pre-dinner blood glucose levels were kept at 105-135mg/dl without relapse for 300 days with injecting only insulin twice a day.
7 patients, who had no atrophy of the pancreas, were treated with iontherapy and insulin for 60 days and then were treated with only iontherapy for 30 days. As the result, pre-dinner blood glucose levels were kept at 115-140mg/dl. In the teleobservation for 300 days, the pre-dinner blood glucose levels rose to 150-180mg/dl in 2 patients (28.6%) who disregard regimen, and relapse didn’t occur in the remaining 5 patients (71.4%). 4) Curative effect of the iontherapy apparatus on abdominal obesity
Table 4. Variation of the girth of abdomen, body weight and blood pressure
Figure imgf000013_0001
A total of 42 patients of Table 4 were previously treated with the pharmacotherapy, but the treatment was not effective. So, they were treated with the iontherapy apparatus. In 33 (78.6%) of the 42 patients, the blood pressure tended to vary before the treatment with the iontherapy apparatus, but it became stable after the treatment and the systolic blood pressure fell 20-60mmHg. ll

Claims

Claims
1. An iontherapy apparatus (10) for the causal treatment of hepatitis, diabetes and obesity, in which an ion resin rod (135) made of cation exchange resin is installed and that comprises:
— a treatment unit (100) comprising a translation motion part (110), a circular motion part (120) and a rotation motion part (130),
— a mounting frame (200) and a supporting structure (300) for installation of the treatment unit (100), — a buffer unit (400) used for setting the treatment unit (100) on the mounting frame (200) and acting as a buffer between the treatment unit (100) and the mounting frame (200),
— a height control unit (500) for controlling the distance between the mounting frame (200) and the supporting structure (300). 2. The iontherapy apparatus according to claim 1 , wherein the ion resin rod (135) is a columnar cation exchange resin 11 millimeters in diameter and 13 millimeters in length.
3. The iontherapy apparatus according to claim 1 , wherein the mounting frame (200) is combined with the supporting structure (300) so that the mounting frame (200) can move up and down by guide shaft (210), guide groove (310) and height control unit (500).
4. The iontherapy apparatus according to claim 1, wherein the buffer unit (400) comprises one or more buffer bands (410) fixed on the mounting frame (200) or one or more buffer springs combined with the mounting frame (200) and the treatment unit (100).
12
5. The iontherapy apparatus according to claim 1 , wherein the height control unit (500) comprises one or more height control bolts (510) and one or more height control nuts (520) combined with the mounting frame (200) and the supporting structure (300). 6. The iontherapy apparatus according to claim 1 , wherein the treatment unit (100) enables the ion resin rod (135) to move along a helical trajectory over its rotation motion in cooperation among the translation motion part (110), the circular motion part (120) and the rotation motion part (130).
7. The iontherapy apparatus according to claim 1 , wherein the translation motion part (110) of the treatment unit (100) comprises a fixed plate (111 ), an electric motor
(112) fixed on the end of the fixed plate (111), a reduction gear (113) coupled with the electric motor (112), a swivel bolt (117) linked to the shaft of the reduction gear (113), a moving nut (118) in screwed combination with the swivel bolt (117), two guide boxes (116) and two guide shafts (114) and a moving plate (115) fixed in the bottom of the two guide boxes (116), and enables the ion resin rod (135) to shuttle.
8. The iontherapy apparatus according to claim 1 , wherein the circular motion part (120) of the treatment unit (100) comprises an electric motor (122) and a reduction gear
(123) fixed to the moving nut (118) of the translation motion part (110), a turning axle
(124) linked to the shaft of the reduction gear (123), a turning plate (125) and a rotator (126) fixed to the turning axle (124) and a stator (127) touched with the rotator (126) and fixed in the bottom of the moving plate (115) of the translation unit (110), and enables the ion resin rod (135) to draw a circle.
9. The iontherapy apparatus according to claim 1 , wherein the rotation motion part (130) of the treatment unit (100) comprises a buffer spring (131) combined with the turning plate (125) of the circular motion part (120), an electric motor (132) combined with
13 the buffer spring (131), a connecting rod (134) connecting the motor shaft with the ion resin rod (135) and the ion resin rod (135) and enables the ion resin rod (135) to turn on its axis.
14
PCT/KP2022/000054 2021-05-12 2022-03-30 Iontherapy apparatus for the causal treatment of hepatitis, diabetes and obesity WO2022239876A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KP202110000686 2021-05-12
KP202110000686 2021-05-12

Publications (1)

Publication Number Publication Date
WO2022239876A1 true WO2022239876A1 (en) 2022-11-17

Family

ID=84029892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KP2022/000054 WO2022239876A1 (en) 2021-05-12 2022-03-30 Iontherapy apparatus for the causal treatment of hepatitis, diabetes and obesity

Country Status (1)

Country Link
WO (1) WO2022239876A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN200984313Y (en) * 2006-08-11 2007-12-05 刘明刚 Bed type automatic whole-body massaging machine
CN203777276U (en) * 2012-11-22 2014-08-20 Seb公司 Massage equipment
CN106176800A (en) * 2016-07-11 2016-12-07 韩源平 The pharmacy application of polycation resin
WO2017116884A1 (en) * 2015-12-30 2017-07-06 L'oreal Iontophoresis massaging system
WO2021075670A2 (en) * 2019-10-18 2021-04-22 대양의료기(주) High frequency treatment handpiece having roller electrodes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN200984313Y (en) * 2006-08-11 2007-12-05 刘明刚 Bed type automatic whole-body massaging machine
CN203777276U (en) * 2012-11-22 2014-08-20 Seb公司 Massage equipment
WO2017116884A1 (en) * 2015-12-30 2017-07-06 L'oreal Iontophoresis massaging system
CN106176800A (en) * 2016-07-11 2016-12-07 韩源平 The pharmacy application of polycation resin
WO2021075670A2 (en) * 2019-10-18 2021-04-22 대양의료기(주) High frequency treatment handpiece having roller electrodes

Similar Documents

Publication Publication Date Title
Caveness Pathology of Radiation Damage to the Normal Brain of the Monkey ¹ William F. Caveness 2 ABSTRACT-Model I: A portion of the monkey brain, the right occipital lobe, was exposed to 3,500 rads of orthovoltage radia-tion in a single dose. This demonstrated a) the delayed, 4 to 5
DE69434121T2 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNE-REINFORCING THERAPY
RU2001110097A (en) THERAPEUTIC COMPOSITIONS (II)
Grossman Effects of stimulation of non-specific thalamic system on locomotor movements in cat
Pickard et al. Controlled trial of cimetidine in acute upper gastrointestinal bleeding.
Gomori et al. Effect of parenterally administered citrate on the renal excretion of calcium.
Frithz et al. The effect of glycerol infusion in acute cerebral infarction
Bolger et al. Short-lasting, Competitive Neuromuscular Blocking Activity in a Series of Azobis-Arylimidazo-[1, 2-a]-Pyridinium Dihalides
WO2022239876A1 (en) Iontherapy apparatus for the causal treatment of hepatitis, diabetes and obesity
Inagaki et al. Inhibitory effect of succinic acid on epithelial cell proliferation of colonic mucosa in rats
Eklund et al. Changes in cyclic 3'5 ‘‐adenosine monophosphate tissue concentration and net fluid transport in the cat's small intestine elicited by cholera toxin, arachidonic acid, vasoactive intestinal polypeptide and 5‐hydroxytryptamine
MacDonald et al. Cutaneous ectopic schistosomiasis.
CN1292759C (en) Treatment of chronic inflammatory diseases with CM 101/GBS toxin
JP3916563B2 (en) Treatment method including administration of substance P
Karatieieva et al. Treatment of pyoinflammatory complications with individually selected ozone dose in patients with diabetes
Sotaniemi Valproic acid in the treatment of nonepileptic myoclonus: report of three cases
Maurice-Williams Mechanism of production of gait unsteadiness by tumours in the posterior fossa.
CN112274644A (en) Medicine for treating spinal and osteoarthropathy and relieving pain thereof
RU2676836C2 (en) Device for treatment of immune function deficiency and regulation of metabolism
Miyake et al. Disintegration of Gallstones and Urinary Calculi in Man: Experimental and Clinical Studies
Deller et al. Renal failure in hypercalcaemic sarcoidosis
US20240032965A1 (en) Methods and systems for treatment of intervertebral disc by intradiscal micro-needle insertion
Shishito et al. Experimental Review on the Neurogenic Bladder Its Pathological Physiology and Biochemistry, and the Effects of Relating Therapeutic Agents
CN101336992A (en) Traditional Chinese medicine preparation for treating early burn or scald
JP3927249B2 (en) Painkiller

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22807574

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE